Research programme: malaria vaccine - GenVec/Laboratory of Malaria Immunology and Vaccinology

Drug Profile

Research programme: malaria vaccine - GenVec/Laboratory of Malaria Immunology and Vaccinology

Latest Information Update: 29 May 2015

Price : $50

At a glance

  • Originator GenVec; Laboratory of Malaria Immunology and Vaccinology
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Malaria

Most Recent Events

  • 21 Apr 2015 Early research in Malaria in USA (Parenteral)
  • 21 Apr 2015 GenVec and Laboratory of Malaria Immunology and Vaccinology (National Institute of Allergy and Infectious Diseases) agree to co-develop vaccines in USA for Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top